The US National Comprehensive Cancer Network (NCCN) frequently recommends beyond the FDA approved indications even for newer, branded drugs, finds new retrospective observational study, raising concern that the NCCN justifies the coverage of costly, toxic cancer drugs based on weak evidence.

The US National Comprehensive Cancer Network (NCCN) frequently recommends beyond the FDA approved indications even for newer, branded drugs, finds new retrospective observational study, raising concern that the NCCN justifies the coverage of costly, toxic cancer drugs based on weak evidence.: http://ift.tt/2G40K1L Read more... http://ift.tt/2Hg6dlw